Tangzhi Pharmaceutical

Tangzhi Pharmaceutical was founded in April 2019, co-founded by experts in glycoscience, a domestic professional team specializing in enzyme directed evolution, and a nucleic acid API industry team. Utilizing multi-enzyme catalyzed biochemical synthesis technology, the company is committed to providing core raw materials and technical solutions for carbohydrates, nucleic acids, and their derivatives to customers at home and abroad. It has established multiple collaborations with pharmaceutical and chemical industry giants both domestically and internationally. The company is headquartered in Wuhan Optics Valley, with R&D centers and pilot-scale modern GMP-level laboratories in Qingdao and Shenzhen. It currently has over 200 employees, including 12 Ph.D. holders and over 40 master's degree holders, with bachelor's degree or above accounting for over 80% of the company. It has an experienced and highly professional multi-level management team. The company has been recognized as a 'National High-tech Enterprise,' 'Hubei Province Innovative Small and Medium-sized Enterprise,' 'Hubei Province Fifth Batch Specialized, Refined, Distinctive, and Innovative Small and Medium-sized Enterprise,' 'Hubei Province 'New Species' and 'Gazelle' Enterprise,' as well as a Wuhan 'High-tech Zone Listed 'Golden Seed' Enterprise' and 'Wuhan Backbone High-tech Gazelle' Enterprise. The company's featured products mainly include: nucleosides and their derivatives, nucleotides (dNTP, NTP and their derivatives), 'cap' analogs, phosphoramidite monomers, monosaccharides, sugar nucleotides, glycolipids, sugar tool enzymes, and many other categories. It can also provide customized product services for customers.